Healthcare
Hofseth BioCare ASA(HOFBF)
Live Price
Offline$0.1666
+0.00% today
1Y Change
+7.48%
Window
Jun 25, 2025 β Jun 17, 2026
- Market Cap
- $530.00M
- Revenue Growth
- -1.2%
- EPS Growth
- -10.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars Β· Jun 25, 2025 β Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Hofseth BioCare ASA (HOFBF) is a Healthcare stock with a market cap of $530.00M and listed on OTC. The stock last traded around $0.17 and up 7.5% across the available one-year price window (Jun 25, 2025 β Jun 17, 2026). Baseline metrics include revenue growth of -1.2%, EPS growth of -10.0%, a dividend yield of 0.0%. What stands out right now is revenue -1.2%, EPS -10.0%, free cash flow -358.7% with operating margin -44.1% and ROIC -50.0%. Valuation is more restrained than many high-expectation growth names at price/sales 2.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines HOFBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.2% vs +7.6% peer median
Operating Margin
Below sector median
-44.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on May 9, 2025, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -1.2% and EPS is at -10.0%, with operating margin around -44.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 May 9, 2025 | β | +0.0% | +0.0% | +7.5% |
2024 Dec 31, 2024 | β | +0.0% | +0.0% | +7.5% |
2024 Sep 30, 2024 | β | +0.0% | +0.0% | +7.5% |
Benchmark Edge
HOFBF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HOFBF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HOFBF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HOFBF and SPY.
Company Overview
Hofseth BioCare ASA
Other OTC
Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Γ lesund, Norway.
- Leadership
- Jon Olav Odegard
- IPO Date
- Aug 22, 2018
- Employees
- 72
- Street Address
- Kipervikgata 13
- Mailing
- Γ lesund, 6003
- Region
- Γ lesund, NO
- Reporting Currency
- USD
- Investor Line
- 47 73 10 22 00
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 2.1
- Price/Book
- β
Growth
- Revenue
- -1.2%
- EPS
- -10.0%
- Free Cash Flow
- -358.7%
Profitability
- Gross Margin
- 18.8%
- Operating Margin
- -44.1%
- Net Margin
- -52.8%
- ROE
- 728.6%
- ROIC
- -50.0%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- 0.67
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.